Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Citi
Federal Trade Commission
Medtronic
Cantor Fitzgerald
Mallinckrodt

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,387,208

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,387,208 protect, and when does it expire?

Patent 9,387,208 protects BRAFTOVI and is included in one NDA.

This patent has forty patent family members in thirty-three countries.

Summary for Patent: 9,387,208
Title:Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of the formulations for treating proliferative diseases, such as solid tumor diseases.
Inventor(s): Verma; Daya (Edison, NJ), Krishnamachan; Yogita (Springfield, NJ), Shen; Xiaohong (Livingston, NJ), Lee; Hanchen (Teaneck, NJ), Li; Ping (Basking Ridge, NJ), Singh; Rajinder (Sewaren, NJ), Tan; LayChoo (Bridgewater, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:14/359,121
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,387,208
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 9,387,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,387,208

PCT Information
PCT FiledNovember 21, 2012PCT Application Number:PCT/US2012/066185
PCT Publication Date:May 30, 2013PCT Publication Number: WO2013/078264

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Federal Trade Commission
Johnson and Johnson
Argus Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.